Ultra-sensitive magnetic immunoassay of HE4 based on surface enhanced Raman spectroscopy

Ming Ge,Chao Wei,Minmin Xu,Congwei Fang,Yaxian Yuan,Renao Gu,Jianlin Yao

DOI: https://doi.org/10.1039/c5ay00977d

IF: 3.1

2015-01-01

Analytical Methods

Abstract:Human epididymis protein 4 (HE4), as a serological marker, has been proposed to be the most promising tumor marker in ovarian cancer diagnosis.

spectroscopy,chemistry, analytical,food science & technology

What problem does this paper attempt to address?

Diagnostic Performance of HE4 and ROMA among Chinese Women.

Yuhuan Shen,Li Zhao,Shiming Lu

DOI: https://doi.org/10.1016/j.cca.2019.10.002

IF: 6.314

2019-01-01

Clinica Chimica Acta

Abstract:OBJECTIVE:Human epididymis protein 4 (HE4) has been suggested as a new biomarker for the detection of ovarian cancer. Because there are few reports on HE4 in terms of ovarian cancer diagnosis in the Chinese population, we evaluated the diagnostic performances of HE4 and the ROMA in Chinese women with pelvic masses.METHODS:The serum concentrations of CA 125 and HE4 in 318 Chinese women with pelvic masses (39 of which were ovarian cancers) were determined.RESULTS:For the discrimination of benign gynecological diseases from ovarian cancer, the sensitivity and specificity values were 87.2% and 75.8% for the ROMA and 51.3% and 97.3% for HE4. The ROMA also showed higher sensitivity than HE4 in both the early and advanced stages. In the ROC curve analysis, the AUC values for ROMA, HE4 and CA 125 were 0.927, 0.907 and 0.785, respectively.CONCLUSIONS:As a new tumor marker, HE4 shows high specificity and efficacy in the Chinese population, while the ROMA that combines HE4 and CA 125 shows high sensitivity and a high Youden's index. These markers should be extended to China since they have good diagnostic performances.
HE4 as a biomarker for ovarian and endometrial cancer management.

Jinping Li,Sean Dowdy,Tracy Tipton,Karl Podratz,Wei-Guo Lu,Xing Xie,Shi-Wen Jiang

DOI: https://doi.org/10.1586/ERM.09.39

2009-01-01

Expert Review of Molecular Diagnostics

Abstract:Ovarian and endometrial cancer will be diagnosed in over 63,000 women in 2009, resulting in 22,000 deaths in the USA. Histologic screening, such as pap smears for detection of cervical cancer, is not feasible for these diseases given difficulty with access to the tissue. Thus, a serum-screening test using a biomarker or panel of biomarkers would be useful to aid in cancer diagnosis, detection of recurrence and as a means to monitor response to therapy. in this review, we focus on the human epididymis protein (HE)4 gene, which appears to have potential as a biomarker for both of these diseases. The structure and methods of detection of HE4 are discussed. Preliminary data show that HE4 may have more potential than cancer antigen 125 in discriminating benign from cancerous ovarian masses, and has the strongest correlation with endometrial cancer of all markers tested to date. Utilizing risk stratification, a panel of biomarkers including HE4 may ultimately be useful for detecting ovarian and endometrial cancer at an early stage in patients at high risk.
Ultrasensitive electrochemical immunosensor for HE4 based on rolling circle amplification

Lingsong Lu,Bei Liu,Zhaohui Zhao,Cuixia Ma,Peng Luo,Chenggui Liu,Guoming Xie

DOI: https://doi.org/10.1016/j.bios.2012.01.004

2012-03-15

Abstract:A novel electrochemical immunoassay system for the detection of human epididymis-specific protein 4 (HE4) was developed. A chitosan-titanium carbide (TiC) nanocomposition film was first electrodeposited onto a tin-doped indium oxide (ITO) electrode at a constant potential. Gold (Au) nanoparticles were then electrodeposited on the surface of the chitosan-TiC film by cyclic voltammetry (CV). The capture antibody (anti-HE4) was adsorbed onto the Au and TiC nanoparticles. After a specific sandwich immunoreaction among the capture antibody, HE4, and biotinylated secondary antibody, biotinylated primer DNA was immobilized on the secondary antibody by biotin-streptavidin system. Appropriate amounts of circular template DNA and biotinylated primer DNA were used for rolling circle amplification (RCA) under optimal conditions. The RCA products provided a large number of sites to link DNA detection probes. Doxorubicin hydrochloride intercalated the CG-GC steps between the RCA products and the DNA detection probes, which was monitored by differential pulse voltammetry (DPV) based on the current signal of doxorubicin hydrochloride. With the above-mentioned amplification factors, the current responded to HE4 linearly in the concentration range of 3-300 pM under optimal detection conditions, with a detection limit of 0.06 pM. Stepwise changes in the microscopic features of the surfaces and electrochemical properties upon the formation of each layer were confirmed by scanning electron microscopy (SEM), atomic force microscopy (AFM), and electrochemical impedance spectroscopy (EIS). This system was successfully employed for the detection of HE4 with good accuracy and renewable ability.
Label-free electrochemical bioplatform based on Au-modified magnetic Fe3O4/α-Fe2O3 hetero-nanorods for sensitive quantification of ovarian cancer tumor marker

Yanling Zhang,Hezhong Ouyang,Shaoshuai Zhang,Yun Ni,Ziye Zhu,Chen Ling,Aolin He,Ruijiang Liu

DOI: https://doi.org/10.1016/j.microc.2023.108546

IF: 5.304

2023-06-01

Microchemical Journal

Abstract:Due to challenges in the ultrasensitive detection of human epididymis protein 4 (HE4), a vital tumor marker for the early diagnosis of ovarian cancer (OC), it is necessary to establish efficient methods for HE4 determination. Recently, electrochemical bioplatforms combined with nanomaterials have shown outstanding performance in the analysis of biological molecules. The surface modification of conductive materials is essential for signal amplification and detection sensitivity. Herein, we developed a novel label-free HE4 electrochemical bioplatform by introducing magnetic Fe3O4/α-Fe2O3 hetero-nanorods (Fe3O4/α-Fe2O3 NRs) as a substrate for signal amplification and DNA aptamer (Apt) probe immobilization in combination with magnetic self-assembly and magnetic separation. Differential pulse voltammetry (DPV) results verified that the platform had excellent specificity for HE4 under optimized conditions and was positively linearly correlated with the logarithm of HE4 concentration (R2 = 0.996) with a linear range of 0.1 pg mL−1 to 1 ng mL−1 and detection limit (LOD) of 27.5 fg mL−1. Moreover, the bioplatform demonstrated promising results for the detection of HE4 in spiked serum samples.

chemistry, analytical
Ultrasensitive Detection of Ovarian Cancer Biomarker Using Au Nanoplate SERS Immunoassay

Gayoung Eom,Ahreum Hwang,Hongki Kim,Jeong Moon,Hyunju Kang,Juyeon Jung,Eun-Kyung Lim,Jinyoung Jeong,Hyun Gyu Park,Taejoon Kang

DOI: https://doi.org/10.1007/s13206-021-00031-2

IF: 4.229

2021-08-09

BioChip Journal

Abstract:Ovarian cancer is the fifth leading cause of cancer-related deaths among women. In particular, it is a high cause of mortality among women in industrialized countries. Human epididymis protein 4 (HE4) has recently emerged as a serological biomarker for the diagnosis of ovarian cancer. Herein, we report the ultrasensitive detection of HE4 using a gold (Au) nanoplate (NPl)-based surface-enhanced Raman scattering (SERS) immunoassay, wherein a capture antibody-immobilized Au NPl acts as an immune substrate and detection antibody-immobilized Au nanoparticles (NPs) serve as immunoprobes. The presence of the target biomarker (HE4) results in the formation of a sandwich structure of Au NPls and NPs, providing strong SERS signals. The developed method allows us to detect HE4 at low concentrations of 10–17 M. The selective detection of HE4 was verified using the Au NPl SERS immunoassay. We anticipate that the current approach could be helpful for the early diagnosis of ovarian cancer and eventually applied for diverse biomarker detection.

chemistry, analytical,nanoscience & nanotechnology,biochemical research methods
A disposable and ultrasensitive immunosensor for the detection of HE4 in human serum samples

Berfin Vural,Meltem Çalışkan,Melike Bilgi Kamaç,Mustafa Kemal Sezgintürk,Sezgintürk, Mustafa Kemal

DOI: https://doi.org/10.1007/s11696-024-03359-9

IF: 2.146

2024-02-28

Chemical Papers

Abstract:Ovarian cancer is described as excessive cell proliferation in the ovaries. It is thought that ovarian cancer and the human epididymis protein 4 (HE4) are closely linked. HE4 is approved as a critical biomarker for the diagnosis and the progression monitoring of the ovarian cancer. In this work, an impedimetric biosensor was fabricated for the analysis of HE4 by modifying the surface of disposable ITO-PET (indium tin oxide-polyethylene terephthalate) sheet with a certain dimensions by 3-Aminopropyl trimethoxy silane (3-APTES). For the interaction between the amino ends of 3-APTES and anti-HE4 antibodies glutaraldehyde was used as a cross-linker. Electrochemical impedance (EIS) and cyclic voltammetry (CV) methods were applied in all electrochemical measurements. Important optimization and characterization experiments have also been completed. Under the optimum conditions, the concentration range for HE4 was obtained between 1 pg/mL and 3000 pg/mL with an LOD and LOQ values of 0.094 pg/mL and 0.3134 pg/mL, respectively. Selectivity experiments revealed that the biosensor showed a great selectivity with its target HE4. The biosensor also showed a good reproducibility with a relative standard deviation (RSD) of slope data calculated as 2.443%. Finally, we applied the biosensor to the commercial real human serum samples for analysis of HE4 and the results of these experiments were encouraging to be used in clinical settings.

chemistry, multidisciplinary
Dual-Mode Photoelectrochemical and Electrochemical Immunosensors for Human Epididymis Protein 4 Based on SPR-Promoted Au Nanoparticle/CdS Nanosheet Heterostructures

Jing-Jing Wei,Gui-Qing Wang,Jia-Ying Zheng,Ai-Jun Wang,Li-Ping Mei,Jiu-Ju Feng

DOI: https://doi.org/10.1021/acsanm.2c03189

IF: 6.14

2022-09-15

ACS Applied Nano Materials

Abstract:As a promising biomarker, human epididymis protein 4 (HE4) shows wide applications for early diagnosis and therapy of ovarian cancer. Herein, heterostructured Au nanoparticles/CdS nanosheet (Au NPs/CdS NS) were initially constructed by two-step electrodeposition and used to build photoelectrochemical (PEC) and electrochemical (EC) dual-mode immunosensors for the detection of HE4. As one of appealing properties, surface Plasmon resonance (SPR) effects of Au NPs endowed the Au NPs/CdS NS heterostructures with highly enhanced PEC and EC signals upon light irradiation, which were gradually weakened by elevating the HE4 concentrations. Under the optimal conditions, the dual-mode sensor displayed wider linear ranges of 0.01–100 and 0.01–200 ng mL–1 for PEC and EC modes, respectively. The detection limits were 1.084 and 1.188 pg mL–1 for PEC and EC detections, respectively. This sensing platform holds great potential for the analysis of other biomarkers in the clinical field.

materials science, multidisciplinary,nanoscience & nanotechnology
A signal-on electrochemical aptasensor for sensitive detection of human epididymis protein 4 based on functionalized metal–organic framework/ketjen black nanocomposite

Rongqin Hu,Zhaode Mu,Feng Gong,Min Qing,Yonghua Yuan,Lijuan Bai

DOI: https://doi.org/10.1007/s10853-023-08627-9

IF: 4.5

2023-06-07

Journal of Materials Science

Abstract:Human epididymis protein 4 (HE4) is a highly sensitive and specific biomarker for diagnosing ovarian cancer. In this work, a new electrochemical aptasensor for rapid and sensitive detection of HE4 was constructed. Firstly, metal–organic framework/ketjen black (NH 2 -MIL-53(Al)/KB) composite with abundant amino groups and large specific surface area was prepared as signal amplifier to anchor gold nanoparticles (AuNPs). Subsequently, signal probe (SP) and a large amount of electroactive toluidine blue (Tb) were attached on AuNPs to form the tracer label, producing a distinct electrochemical detection signal. Moreover, Ni 3 (HITP) 2 was modified by poly(diallyldimethylammonium chloride, PDDA) to obtain PDDA/Ni 3 (HITP) 2 , and then it was covered with deposited gold nanocrystals (DpAu) to form the sensing platform, which increased the electrical conductivity, specific surface area and the loading of triple-helix assembled probes (TAP). Target HE4 was bound to its aptamer in the outer layer of the TAP, leaving a separate capture probe (CP) on the electrode surface that can bind with the tracer label. The proposed aptasensor for HE4 detection showed a wide linear range from 1 to 10 nM with a detection limit of 0.41 fM. In addition, the aptasensor has good selectivity, stability and reproducibility. More importantly, this method showed satisfactory results in clinical serum sample analysis compared with ELISA, possessing application prospects in ovarian cancer diagnosis.

materials science, multidisciplinary
Human Epididymis Protein 4 (He4) As A Serum Tumor Biomarker In Patients With Ovarian Carcinoma

Xiaohong Chang,Xue Ye,Li Dong,Hongyan Cheng,Yexia Cheng,Lirong Zhu,Qinping Liao,Yang Zhao,Li Tian,Tianyun Fu,Jun Chen,Heng Cui

DOI: https://doi.org/10.1097/IGC.0b013e31821a3726

2011-01-01

International Journal of Gynecological Cancer

Abstract:Background: Ovarian cancer remains a leading cause of death from gynecological malignancy. Early diagnosis is the most important determinant of survival. For more than 25 years, cancer antigen 125 (CA 125) has been the criterion standard biomarker for the diagnosis and management of women with epithelial ovarian cancer. This study evaluated human epididymis protein 4 (HE4), a novel ovarian cancer biomarker, both alone and in combination with CA 125 as a diagnostic marker for ovarian cancer in a Chinese population.Methods: Sera from 491 Chinese women with ovarian cancer or nonmalignant disorders and healthy women were analyzed. Sensitivities and specificities for both biomarkers and the combination were determined using predefined cutoffs (HE4 >150 pmol/L and CA 125 >35 U/mL) and receiver operator characteristic curves to define cutoffs based on 95% and 98% sensitivities.Results: At baseline, serum HE4 and CA 125 levels were significantly higher in the ovarian cancer group versus the 5 reference groups. Using predefined cutoffs, HE4 specificity for ovarian cancer ranged from 90% to 100%; CA 125 specificity ranged from 36% (benign gynecologic disease) to 99%. Combining both markers yielded specificity for ovarian cancer of 100%. Using receiver operator characteristic curve analysis, the cutoff for 95% and 98% specificity was 102.6 and 150.2 pmol/L for HE4, respectively, and 127.2 and 325.5 U/mL for CA 125, respectively; the sensitivity of CA 125 for distinguishing ovarian cancer from benign gynecologic disease was 54% (95% specificity) and 28% (98% specificity), improving to 78% and 68%, respectively, with the addition of HE4.Conclusions: Human epididymis protein 4 used in conjunction with CA 125 yields improved specificity for ovarian cancer compared with the use of CA 125 alone, generally similar to results seen in non-Chinese populations.
High-Density Gold Nanoparticles Implanted on Mg/Fe LDH Nanoflowers Assisted Lateral Flow Immuno-Dipstick Assay for Visual Detection of Human Epididymal Protein 4

Hao Liu,Mei-Xia Wu,Shou-Nian Ding

DOI: https://doi.org/10.3390/bios12100797

2022-09-28

Biosensors

Abstract:The timelier and more accurate the diagnosis of the disease, the higher the patient's survival rate. Human epididymal protein 4 (HE4) has great significance as a biomarker of concern for reflecting ovarian cancer. Herein, we prepared a novel optical label that can be used in lateral-flow immuno-dipstick assay (LFIA) for sensitive visual detection of HE4 by implanting hydrophobic gold nanoparticles (Au NPs) at high density in Mg/Fe LDH nanoflowers (MF NFs). MF NFs with large specific surface area, high porosity, abundant active binding sites, and stable structure were employed for the first time as templates to directly anchor Au NPs in the organic phase. After simple modification with an optimized amount of branched polyethyleneimine, not only could MF@Au NFs be dispersed in the aqueous phase, but also amino functional groups were introduced on its surface to facilitate subsequent antibody coupling steps. The limit of detection reaches 50 pM with a detection range of 50 to 1000 pM. This work initially explored how MF NFs can be used to load signal labels with ideal stability and signal amplification capabilities, which greatly improves the practicability of LFIA and highlights its important role in the field of rapid diagnostics.
HE4 As a Serum Biomarker for ROMA Prediction and Prognosis of Epithelial Ovarian Cancer

Wen-Ting Chen,Xiang Gao,Xiao-Dian Han,Hui Zheng,Lin Guo,Ren-Quan Lu

DOI: https://doi.org/10.7314/apjcp.2014.15.1.101

2014-01-01

Asian Pacific Journal of Cancer Prevention

Abstract:BACKGROUND AND PURPOSE:Human epididymis protein 4 (HE4) has been suggested to be a novel biomarker of epithelial ovarian cancer (EOC). The present study aimed to evaluate and compare HE4 with the commonly used marker, carbohydrate antigen 125 (CA125), in prediction and therapy-monitoring of EOC.PATIENTS AND METHODS:Serum HE4 concentrations from 123 ovarian cancer patients and 174 controls were measured by Roche electrochemiluminescent immunoassay (ECLIA). Risk of ovarian malignancy algorithm (ROMA) values were calculated and assessed. In addition, the prospects of HE4 detection for therapy-monitoring were evaluated in EOC patients.RESULTS:The ROMA score could classify patients into high- and low-risk groups with malignancy. Indeed, lower serum HE4 was significantly associated with successful surgical therapy. Specifically, 38 patients with EOC exhibited a greater decline of HE4 compared with CA125. In contrast, elevation of HE4 better predicted recurrence (of 46, 11 patients developed recurrence, and with it increased HE4 serum concentrations) and a poor prognosis than CA125.CONCLUSIONS:This study suggests that serum HE4 levels are closely associated with outcome of surgical therapy and disease prognosis in Chinese EOC patients.
The Role of HE4 in Ovarian Cancer: Inhibiting Tumour Cell Proliferation and Metastasis.

L. Gao,H. Y. Cheng,L. Dong,X. Ye,Y. N. Liu,X. H. Chang,Y. X. Cheng,J. Chen,R. Q. Ma,H. Cui

DOI: https://doi.org/10.1177/147323001103900507

2011-01-01

Journal of International Medical Research

Abstract:As a promising biomarker, human epididymis protein 4 (HE4) has been widely used for the early detection and differential diagnosis of ovarian cancer. This study evaluated the function of HE4 in the carcinogenesis and progression of ovarian cancer. An enzyme immunometric assay, used to detect HE4 in the serum of ovarian cancer patients, showed that the protein could discriminate between malignant and benign ovarian tumours with high specificity. An exogenous HE4 gene was transfected into ovarian cancer cell lines and an immortalized ovarian epithelial cell line. Compared with the controls, HE4 overexpression significantly promoted cell apoptosis and adhesion. Overexpression of HE4 also led to significant inhibition of cell proliferation, migration and invasiveness in vitro, as well as xenograft tumour formation in vivo. This is the first report to demonstrate the functional importance of HE4 in multiple cellular processes and indicates that HE4 may play a protective role in the progression of ovarian cancer.
Studies on the Value of Human Epididymis Protein 4 in Patients with Ovarian Cancer

卢仁泉,郭林,胡娟

DOI: https://doi.org/10.3760/cma.j.issn.1009-9158.2009.12.012

2009-01-01

Abstract:Objective To evaluate serum human epididymis protein 4 (HE4) as a biomarker for ovarian cancer. Methods HE4 was determined by ELISA in ovarian cancer patients ( n = 82 ) , benign ovarian disease patients ( n = 26 ) and healthy controls ( n = 40) . Results The level of HE4 was significantly higher in ovarian cancer group(46. 6 pmol/L) than that in benign ovarian disease group(31. 5 pmol/L) and healthy control group(24.0 pmol/L) in premenopausal women ( U = 95. 5 and 100.0, P< 0. 01, respectively). The level of HE4 in ovarian cancer group( 139. 0 pmol/L) was also significantly higher than that in benign ovarian disease group(35.4 pmol/L) and in healthy control group (27.7 pmol/L) in postmenopausal patients ( U = 25. 0 and 49. 0, P < 0. 01 , respectively ). The receiver operation characteristic (ROC) analysis showed the cut-off value to discriminate cancer patients from controls in premenopausal women group was established at 35. 7 pmol/L for HE4 ( sensitivity 71. 4% ; specificity 80. 0% ) , while the corresponding cut-off value in postmenopausal women group was set at 54. 5 pmol/L ( sensitivity 87. 0% ; specificity 92. 9% ). The diagnostic efficacy of HE4 was higher than carbohydrate antigen 125 ( CA125). The high risk of malignancy group was defined as the ROMA value >3. 5% for premenopausal women and > 12. 5% for postmenopausal women. With the progression of ovarian carcinoma, the levels of HE4 as well as the sensitivity were increased. HE4 concentrations were higher in patients with lymph node metastasis than those without metastasis ( U = 34. 0 and 77. 0 in premenopausal and postmenopausal women, P < 0. 01 , respectively). Changes of HE4 concentrations were correlated with tumor response. Elevated levels of HE4 were found in recurrent disease patient, and the levels were decreased while the patients were sensitive to therapy. Conclusion HE4 determination is helpful in the diagnosis and prognosis of ovarian cancer.
Diagnostic role of urine human epididymis protein 4 in ovarian cancer

Antonija Hanžek,Christian Siatka,Anne-Cécile E Duc

DOI: https://doi.org/10.11613/BM.2024.030502

2024-10-15

Abstract:Ovarian cancer is the 8th most common malignancy in women and the deadliest gynecological cancer. Due to the non-specific symptoms and the lack of effective diagnostic methods, late diagnosis remains the main barrier for improving the poor prognosis. Human epididymis protein 4 (HE4) is a protein overexpressed in ovarian cancer, but not in healthy individuals or benign conditions. The aim of this review article is to evaluate the laboratory aspect and potential clinical application of urine HE4. The methodology is presented, together with discussion on preanalytical, analytical and postanalytical phase of HE4 detection using urine. Moreover, we present the diagnostic role of urine HE4 in differential diagnosis, chemotherapy response, detection of recurrence and detection of low-malignant potential tumors. It has been found that urine HE4 presents as a promising, non-invasive tumor marker for detection and monitoring of ovarian cancer. However, standardization of the HE4 detection process is needed prior to implementation in clinical diagnostics.
Magnetic separation and immunoassay of multi-antigen based on surface enhanced Raman spectroscopy.

Shuai Chen,Yaxian Yuan,Jianlin Yao,Sanyang Han,Renao Gu

DOI: https://doi.org/10.1039/c0cc05321j

IF: 4.9

2011-01-01

Chemical Communications

Abstract:A novel and highly sensitive immunoassay method based on surface enhanced Raman spectroscopy (SERS) and magnetic particles has been developed. This method exhibits great potential application in bio-separation and immunoassay.
Ultrasensitive detection of IgE levels based on magnetic nanocapturer linked immunosensor assay for early diagnosis of cancer

Yongxin Liu,Mengda Cao,Zhongxi Huang,Changmin Yu,Naidi Yang,Qiong Wu,Liang Shi,Wenjie Duan,Yi Zhu,Jifu Wei,Lin Li,Wei Huang

DOI: https://doi.org/10.1016/j.cclet.2021.08.117

IF: 9.1

2022-04-01

Chinese Chemical Letters

Abstract:Rapid and accurate detection of immunoglobulin E (IgE) in serum and reduction of serum dosage are of great significance for clinical detection. Herein, we described a rapid magnetic separation of IgE from patient serum based on Fe3O4@SiO2 sdab as the capture probe and multiple horseradish peroxidase (HRP)-labeled antibodies linked gold nanoparticles (AuNPs) as chemiluminescence (CL) signal amplifier for ultrasensitive detection of total IgE. Results showed that the limit of detection of our immunosensor system in serum samples was 0.03 kU/L, which is lowest in comparison with current methods, and far lower than that of ImmunoCAP for IgE detection (0.1 kU/L). Furthermore, our immunosensor possessed satisfied repeatability and accuracy, as well as good stability. In comparison with the ImmunoCAP for the quantitative detection of IgE, highly consistent results were achieved in 20 serum samples. Specially, this method was also successfully utilized for assessing the IgE traces in breast cancer patients, which provides a new idea for the diagnosis of early cancer. Therefore, we believe that such versatile immunosensor will offer an alternative method for the on-site monitoring and determination of various IgE-related diseases.

chemistry, multidisciplinary
Ultrasensitive analysis of heat shock protein 90α with antibodies orderly arrayed on a novel type of immunoprobe based on magnetic COFs

Rui Zhai,Xiaoyun Gong,Jie Xie,Yifeng Yuan,Fei Xu,You Jiang,Zejian Huang,Xinhua Dai,Yangjun Zhang,Xiaohong Qian,Xiang Fang

DOI: https://doi.org/10.1016/j.talanta.2018.09.010

IF: 6.1

2019-01-01

Talanta

Abstract:The early diagnosis of liver cancer by target biomarkers is of great significance for improving the survival rate of cancer patients. However, it is still a challenging task to sensitively detect circulating protein biomarkers due to decreased binding activity of antibodies originating from uncontrolled orientation of immobilization on the surface of a solid matrix. In this work, a novel immunoaffinity probe, Fe3O4@TpBD-DSS-Ab-MEG, based on magnetic COFs with ordered arrangement of anchored antibodies has been developed and applied for the first time to detection of a cancer biomarker, heat shock protein 90alpha (Hsp90α). The fabricated composites possess favorable features from magnetic cores and COF shells, including strong magnetic responses (7.96 emu g-1), ordered active groups, a large amount of immobilized antibodies (111.7 μg/mg), good solvent and thermal stability. Fe3O4@TpBD-DSS-Ab-MEG demonstrated low detection limit (50 pg/mL), high selectivity (Hsp90α:BSA = 1:1000), desirable repeatability and good stability for Hsp90α immunocapture. Compared with other immunoprobes, our materials showed higher selectivity and sensitivity, which were mainly attributed to regular arrays of surface antibodies. Furthermore, samples containing Hsp90α at the concentration of 1 µg/mL in human plasma were used to test our immunoprobe, and 2 peptides of Hsp90α were successfully observed. The proposed non-invasive immunoassay strategy offers enhanced ability to control the orientation of immobilized antibodies and great promise for accurate analysis of the liver cancer biomarker Hsp90α in a complicated biological matrix. In addition, the facile preparation of magnetic COFs support and the satisfactory analytical performance made the newly developed immunoprobe a potential tool for sensitive detection of other cancer biomarkers in clinical diagnosis.
A Portable Microfluidic Platform for Ultra-Sensitive Detection of Ovarian Cancer Biomarkers Via Cascade Signal Amplification

Yuzhen Wang,Wenxiu Long,Yanping Wang,Yuanyue Han,Fei Zeng,Jingjing Li,Bangshun He,Yujun Song,Yanfeng Gao

DOI: https://doi.org/10.1016/j.cej.2024.158289

IF: 15.1

2024-01-01

Chemical Engineering Journal

Abstract:Early detection of ovarian cancer is crucial for improving treatment outcomes and increasing survival rates, as this malignancy is often diagnosed at an advanced stage due to the lack of specific early symptoms. In this study, we present a novel diagnostic platform integrating platinum nanozyme-induced cascade signal amplification with a gas-driven visual amplification chip (VAC) for the sensitive and specific detection of the ovarian cancer biomarkers CA125 and HE4. This system leverages a sandwich complex formed by capture antibody-functionalized magnetic silica nanoparticles (Ab1-MSNPs) and detection antibody-functionalized platinum nanoparticles (Ab2-PtNPs) in the presence of target antigens. The PtNPs’ peroxidase-like activity catalyzes dopamine polymerization, leading to polydopamine (PDA) deposition and subsequent capture of 4-mercaptophenylboronic acid-modified PtNPs, amplifying the detection signal. The VAC achieved exceptional sensitivity, with detection limits as low as 0.001 U mL−1 for CA125 and 0.1 pg mL−1 for HE4, surpassing traditional methods. Finally, the platform demonstrated a strong correlation with electrochemiluminescence assays, making it a promising tool for point-of-care testing and early ovarian cancer detection in clinical settings.
Serum HE4 As a Useful Biomarker in Discriminating Ovarian Cancer from Benign Pelvic Disease

Hong Zheng,Yunong Gao

DOI: https://doi.org/10.1097/igc.0b013e318249bee7

2012-01-01

International Journal of Gynecological Cancer

Abstract:Objective To evaluate the role of the novel tumor marker human epididymal secretory protein E4 (HE4) in discriminating ovarian cancer from benign pelvic disease in patients with a pelvic mass. Methods Serum samples from 131 patients with epithelial ovarian cancer (EOC) and 126 patients with various benign pelvic diseases were collected preoperatively and tested for cancer antigen (CA)125 and HE4 levels. Receiver operator characteristic curves were constructed, and the area under the curve (AUC) was compared between the markers. Results The median CA125 and HE4 levels were significantly higher in the patients with EOC than in those with benign disease (P < 0.001). Using benign controls as the comparison group for all cases, the AUC for combined HE4 and CA125 (0.955) was significantly higher than that for HE4 (0.941) or CA125 alone (0.924; P < 0.05). A comparison of premenopausal benign controls to EOC cases showed that the AUC for combined HE4 and CA125 (0.97) was significantly higher than that for CA125 (0.93; P < 0.004). The AUC for HE4 was significantly higher compared to that of CA125 in discriminating EOC from ovarian endometriosis (0.969 vs 0.904; P = 0.014) and pelvic inflammatory disease (0.909 vs 0.819; P = 0.034). Conclusion Serum HE4 testing is a more powerful tool than CA125 assay to discriminate EOC from ovarian endometriosis and pelvic inflammatory disease. For patients with a pelvic mass, especially premenopausal patients, the serum concentration of HE4 adds valuable information to CA125 in identifying patients with EOC from those with benign pelvic disease.
An Ultrasensitive Polydopamine Bi-Functionalized SERS Immunoassay for Exosome-Based Diagnosis and Classification of Pancreatic Cancer.

Teng-Da Li,Ren Zhang,Hui Chen,Zhi-Peng Huang,Xin Ye,Hui Wang,An-Mei Deng,Ji-Lie Kong

DOI: https://doi.org/10.1039/c8sc01611a

IF: 8.4

2018-01-01

Chemical Science

Abstract:Ultrasensitive polydopamine bi-functionalized surface enhanced Raman scattering immunoassay expedites exosome-based diagnosis and classification of pancreatic cancer.

Ultra-sensitive magnetic immunoassay of HE4 based on surface enhanced Raman spectroscopy

Diagnostic Performance of HE4 and ROMA among Chinese Women.

HE4 as a biomarker for ovarian and endometrial cancer management.

Ultrasensitive electrochemical immunosensor for HE4 based on rolling circle amplification

Label-free electrochemical bioplatform based on Au-modified magnetic Fe3O4/α-Fe2O3 hetero-nanorods for sensitive quantification of ovarian cancer tumor marker

Ultrasensitive Detection of Ovarian Cancer Biomarker Using Au Nanoplate SERS Immunoassay

A disposable and ultrasensitive immunosensor for the detection of HE4 in human serum samples

Dual-Mode Photoelectrochemical and Electrochemical Immunosensors for Human Epididymis Protein 4 Based on SPR-Promoted Au Nanoparticle/CdS Nanosheet Heterostructures

A signal-on electrochemical aptasensor for sensitive detection of human epididymis protein 4 based on functionalized metal–organic framework/ketjen black nanocomposite

Human Epididymis Protein 4 (He4) As A Serum Tumor Biomarker In Patients With Ovarian Carcinoma

High-Density Gold Nanoparticles Implanted on Mg/Fe LDH Nanoflowers Assisted Lateral Flow Immuno-Dipstick Assay for Visual Detection of Human Epididymal Protein 4

HE4 As a Serum Biomarker for ROMA Prediction and Prognosis of Epithelial Ovarian Cancer

The Role of HE4 in Ovarian Cancer: Inhibiting Tumour Cell Proliferation and Metastasis.

Studies on the Value of Human Epididymis Protein 4 in Patients with Ovarian Cancer

Diagnostic role of urine human epididymis protein 4 in ovarian cancer

Magnetic separation and immunoassay of multi-antigen based on surface enhanced Raman spectroscopy.

Ultrasensitive detection of IgE levels based on magnetic nanocapturer linked immunosensor assay for early diagnosis of cancer

Ultrasensitive analysis of heat shock protein 90α with antibodies orderly arrayed on a novel type of immunoprobe based on magnetic COFs

A Portable Microfluidic Platform for Ultra-Sensitive Detection of Ovarian Cancer Biomarkers Via Cascade Signal Amplification

Serum HE4 As a Useful Biomarker in Discriminating Ovarian Cancer from Benign Pelvic Disease

An Ultrasensitive Polydopamine Bi-Functionalized SERS Immunoassay for Exosome-Based Diagnosis and Classification of Pancreatic Cancer.